{
	"kja6j05jText": "Alv<span class=\"_ _2\"></span>are<span class=\"_ _c\"></span>z E et al. 2<span class=\"_ _c\"></span>0<span class=\"_ _c\"></span>1<span class=\"_ _3\"></span>2<span class=\"_ _3\"></span><span class=\"fs1 v1\">1</span>",
	"kja6j05kText": "<div style=\"line-height: 1.1;\">Randomised, double-blind, fixed-dose, placebo-controlled, active reference study recruited<br style=\"\"><span class=\"ls4c wsb\">randomised patients from 49 psychiatric settings in 11 countries (Australia, Austria, Canada,<br style=\"\">Czech Republic, Finland, France, Italy, Malaysia, Slovakia, Spain and Sweden).</span><div style=\" margin-top:5px;\"><span class=\"ls4c wsb\" style=\"\"><div style=\"\">Study objective: <span class=\"ff3\" style=\"\">Investigate the efficacy, safety and tolerability of two fixed doses (5 and 10 mg/day)</span></div><div class=\"ff3\">of Brintellix® vs. placebo after six weeks of treatment in adult patients with MDD.</div></span></div></div>",
	"kja6j05lText": "Key inclusion criteria ",
	"kja6j05mText": "P<span class=\"_ _c\"></span>atients with MDD<span class=\"_ _0\"></span> <br>presenting with a current <br>major depressive episode <br>according to DSM-IV<span class=\"_ _2\"></span>-<span class=\"_ _c\"></span>TR <br><span class=\"ws81\">criteria<span class=\"_ _0\"></span> </span>",
	"kja6j05nText": "18-65 years of age<span class=\"_ _0\"></span> ",
	"kja6j05oText": "MADRS total score ≥30 at <br>baseline visit",
	"kja6j05pText": "<div style=\"line-height: 1.2;\"><div style=\"text-align: center;\">T<span class=\"_ _3\" style=\"\"></span>wo-week</div><div style=\"text-align: center;\">double-blind<br style=\"\"></div><div style=\"text-align: center;\">taper period<br style=\"\"></div></div>",
	"kja6j05sText": "Back",
	"kja6j05tText": "V<span class=\"_ _2\"></span>enlafaxine (n=113)",
	"kja6j05uText": "Brintellix® 5 mg (n=108)",
	"kja6j05vText": "Placebo (n=105)",
	"kja6j05wText": "Brintellix® 10 mg (n=100)",
	"kja6j05xText": "Six-week double-blind tre<span class=\"_ _2\"></span>atment period",
	"kja6j05yText": "Randomisation <br><span class=\"ls2a ws85\">1:<span class=\"_ _0\"></span>1:1:1<span class=\"_ _1\"> </span> <br><span class=\"ls4d ws90\">(<span class=\"_ _0\"></span>A<span class=\"_ _0\"></span>P<span class=\"_ _1\"></span>T<span class=\"_ _0\"></span>S<span class=\"_ _0\"></span> n<span class=\"_ _0\"></span>=<span class=\"_ _1\"></span>42<span class=\"_ _0\"></span>6)</span></span>",
	"kja6j05zText": "Efficacy and&nbsp;<div>tolerability&nbsp;<div>were assessed&nbsp;</div><div>at screening,&nbsp;</div><div>baseline and&nbsp;</div><div>after 1, 2, 3, 4,&nbsp;</div><div>5 and 6 weeks<br></div></div>",
	"kja6j060Text": "Primary ef<span class=\"_ _0\"></span>ficac<span class=\"_ _0\"></span>y analysis: <span class=\"ff3 ls36 wsb\">based o<span class=\"_ _2\"></span>n the MADR<span class=\"_ _2\"></span>S total sc<span class=\"_ _2\"></span>ore <br>ad<span class=\"_ _2\"></span>justin<span class=\"_ _2\"></span>g for mu<span class=\"_ _2\"></span>ltipl<span class=\"_ _2\"></span>icity using a h<span class=\"_ _2\"></span>iera<span class=\"_ _2\"></span>chi<span class=\"_ _2\"></span>al testin<span class=\"_ _2\"></span>g proc<span class=\"_ _2\"></span>edur<span class=\"_ _2\"></span>e <br>star<span class=\"_ _0\"></span>ting with th<span class=\"_ _2\"></span>e hig<span class=\"_ _2\"></span>hest dose vs. pl<span class=\"_ _2\"></span>ace<span class=\"_ _2\"></span>bo.</span>",
	"kja6j061Text": "Secondary ef<span class=\"_ _0\"></span>ficacy analysis: <span class=\"ff3\">chang<span class=\"_ _2\"></span>e in the f<span class=\"_ _2\"></span>oll<span class=\"_ _2\"></span>owi<span class=\"_ _2\"></span>ng <br>varia<span class=\"_ _2\"></span>bles w<span class=\"_ _2\"></span>ere m<span class=\"_ _2\"></span>easu<span class=\"_ _2\"></span>red fr<span class=\"_ _2\"></span>om base<span class=\"_ _2\"></span>lin<span class=\"_ _2\"></span>e to ea<span class=\"_ _2\"></span>ch visit: <br><span class=\"ls3f ws6c\">MADR<span class=\"_ _2\"></span>S total scor<span class=\"_ _2\"></span>e, HAMD<span class=\"_ _c\"></span><span class=\"fs1c ls3e ws82 v3\">24<span class=\"_ _0\"></span><span class=\"fs18 ls38 ws7e v8\"> total<span class=\"_ _0\"></span> score, C<span class=\"_ _2\"></span>GI-<span class=\"_ _0\"></span>l and CGI-S <br><span class=\"ls36 wsb\">scores, HA<span class=\"_ _2\"></span>MA total sc<span class=\"_ _2\"></span>ore<span class=\"_ _c\"></span>, remissi<span class=\"_ _2\"></span>on an<span class=\"_ _2\"></span>d respo<span class=\"_ _2\"></span>nse at al<span class=\"_ _c\"></span>l<span class=\"_ _0\"></span> <br><span class=\"ls47 ws6d\">time<span class=\"_ _0\"></span> point<span class=\"_ _0\"></span>s.</span></span></span></span></span></span>",
	"Brintellix_77ecbe81bb": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_77552a1416": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Alvarez E et al. Int J Neuropsychopharmacol 2012;15:589-600.</div>"
}
